Search clinical trials for: Inadequate glycaemic control

Total 46125 results

University Hospital, Toulouse

Completed

Efficacy of Periodontal Treatment on Glycaemic Control in Diabetic Patients (DIAPERIO)

Diabetes

France
AbbVie

Withdrawn

Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate

Rheumatoid Arthritis (RA)

China
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Type 2 Diabetes Mellitus
Astellas Pharma Korea, Inc.

Completed

A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin

Type 2 Diabetes Mellitus

Korea, Republic of
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin (IMPRESSION)

Type 2 Diabetes Mellitus

Russian Federation
Hoffmann-La Roche

Completed

A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy (TOSCA)

Rheumatoid Arthritis

France
Loughborough University
Yakult Honsha Co., LTD

Completed

Effect of Yakult Ingestion on Diet-induced Insulin Resistance in Humans

Type 2 Diabetes Mellitus | Insulin Resistance | Insulin Sensitivity

United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin (LIRA-SWITCH™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Canada, Hungary, India, Spain, Puerto Rico
University of Manitoba
Manitoba Institute of Child Health

Terminated

The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial (VIGOR)

Type 1 Diabetes

Canada
Sanofi

Completed

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist (BRIGHT)

Diabetes Mellitus, Type 2

Israel, Czechia, Greece, Italy, United States, Bulgaria, Croatia, Denmark, France, Hungary, Romania, Serbia, Slovakia, Sweden, Switzerland, United Kingdom
Merck Sharp & Dohme LLC
Pfizer

Completed

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

Type 2 Diabetes Mellitus
AstraZeneca
Bristol-Myers Squibb

Completed

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 1)

Type 1 Diabetes Mellitus

United States, Austria, Germany, Italy, Spain, United Kingdom, Belgium, Mexico, Israel, Hungary, Canada, Australia, Denmark, Sweden, Romania, France, Finland
Merck Sharp & Dohme LLC
Pfizer

Completed

Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Type 2 Diabetes Mellitus
King's College London

Completed

Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes (TITANIC)

Type 1 Diabetes Mellitus | Lipohypertrophy

United Kingdom
Takeda

Completed

Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy (ADD)

Type II Diabetes Mellitus

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Type 2 Diabetes Mellitus
Nemours Children's Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control (CGM-Teens)

Type 1 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)

Type 2 Diabetes Mellitus
Nanjing First Hospital, Nanjing Medical University

Unknown

The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine

Type2 Diabetes
Novo Nordisk A/S

Terminated

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Inflammation | Rheumatoid Arthritis

United States, Mexico, Russian Federation, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Poland, Ukraine, Hungary
Merck Sharp & Dohme LLC

Completed

Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Type 2 Diabetes Mellitus
Forschungsinstitut der Diabetes Akademie Mergentheim
German Federal Ministry of Education and Research; Helmholtz Zentrum München; German Diabetes Center and other collaborators

Completed

Depression and Diabetes Control Trial (DDCT)

Depression | Diabetes Mellitus | Diabetes Complications | Depressive Symptoms | Emotional Distress | Affective Disorders

Germany
Merck Sharp & Dohme LLC

Terminated

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

Type 2 Diabetes Mellitus
UCB Pharma SA
Parexel

Completed

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Rheumatoid Arthritis

Romania, United States, Australia, Austria, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Ireland, Italy, Mexico, Monaco, Poland, Portugal, Spain, Switzerland, United Kingdom
Merck Sharp & Dohme LLC

Terminated

A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

Type 2 Diabetes Mellitus
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Completed

Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin (SPECIFY)

Type 2 Diabetes

China
Milton S. Hershey Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC) (TALC)

Asthma

United States
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Type 2 Diabetes

United States, Hungary, Mexico, South Africa, Romania, Poland
University of Adelaide
Salk Institute for Biological Studies

Terminated

Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? (RESHAPE2)

Insulin Resistance | Type2 Diabetes

Australia
Shionogi

Completed

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

Type 2 Diabetes Mellitus

United States
University of Aberdeen
NHS Greater Glasgow and Clyde; NHS Grampian; University of Glasgow

Completed

Mindfulness-based Cognitive Therapy to Improve Emotional Wellbeing and Glycaemic Control in Diabetes (MILESTONE)

Depression | Diabetes | Anxiety

United Kingdom
University of Leeds

Completed

The Effects of Citric and Malic Acid Found in Pomegranate Juice on Glycaemic Response to White Bread.

Hyperglycemia, Postprandial

United Kingdom
Hoffmann-La Roche

Completed

A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Rheumatoid Arthritis

Denmark, Finland, Norway, Sweden
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (PAOLA)

Acromegaly

United States, Italy, Belgium, Saudi Arabia, Spain, France, Germany, Canada, United Kingdom, Colombia, Brazil, Israel, Turkey, Romania, Norway, Poland, Russian Federation, Argentina
MedtronicNeuro

Terminated

Intrathecal Morphine Compared to Conventional Medical Management for Pain Control and Opioid-related Side Effects (CONVERT-TDD)

Chronic Pain

United States
Smt. Kashibai Navale Medical College and General...

Completed

Effect of Vitamin B12 Supplementation on Glycaemic Control in Uncontrolled Hyperhomocysteinemic Type 2 Diabetic Patients

Type 2 Diabetes | Vitamin B12 Deficiency | Hyperhomocysteinemia

India
University of Reading

Completed

A Lifestyle Intervention for Type 2 Diabetes Patients in Kuwait and Its Impact on Glycaemic Control

Diabetes, Type 2 | Diabetes Mellitus, Noninsulin-Dependent

United Kingdom, Kuwait
INSYS Therapeutics Inc

Withdrawn

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

Dravet Syndrome
INSYS Therapeutics Inc

Withdrawn

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome
University Hospital, Strasbourg, France
Novartis

Completed

A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

Haemodialyzed, Type 2 Diabetes

France
GlaxoSmithKline

Terminated

Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy

Arthritis, Rheumatoid

Poland, Russian Federation, Argentina, Belgium, Peru, Spain, Australia, Czechia, South Africa, Chile, Hungary, United Kingdom, Romania

3

Subscribe